Ancora Heart
CA - Santa ClaraBiotechnology
Focus: Ancora Heart is a cardiac device biotech founded in 2021, focused on minimally invasive procedures for mitral valve regurgitation and heart failure. The company is early-stage and pre-revenue, headquartered in Santa Clara, CA.
Profile data last refreshed 30m ago · AI intelligence enriched 2w ago
Open Jobs
3
Should You Work at Ancora Heart?
AI assessmentEarly-stage cardiac device bet with meaningful pipeline depth, but pre-revenue status and minimal hiring velocity make this a high-risk, high-reward play best suited for equity-motivated, risk-tolerant professionals.
Why Work Here
- Ground-floor opportunity at a focused cardiac-device innovator with a proprietary AccuCinch platform targeting a large unmet need in heart failure management
Data completeness
2/9 — Limited
Company HealthSolid
Pipeline
Early-stage
9 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Left ventricular restoration
Heart FailureClinical Trials (1)
NCT03183895Evaluate the Safety and Performance of the AccuCinch® Ventricular Repair System - The CorCinch-EU Study
N/AHelp build intelligence for Ancora Heart
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.